Ir para o conteúdo

The Journal of Infectious Diseases

@jidjournal.bsky.social did:plc:j7joregvysxlyvog2l3xewmp

In publication since 1904, JID is the premier global journal for original research on infectious diseases. JID is an official journal of @idsainfo.bsky.social

No Bluesky desde

Seguidores
6.861
Seguindo
1
Posts
1.158
Dias nos rankings
0

Resumo

The Journal of Infectious Diseases (@jidjournal.bsky.social) é um usuário do Bluesky desde 24 outubro 2023. Tem 6.861 seguidores, segue 1 contas e publicou 1.158 posts.

Aparições nos rankings

Os melhores dias em que posts desta conta entraram na lista diária do Debya.

Esta conta ainda não apareceu em um ranking diário.

Posts curtidos recentemente

Curtidas públicas da rede Bluesky.

  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks blog: Learn more postnatal CMV infection in preterm infants, how rates of IPD since the COVID-19 pandemic shape vaccine recommendations and other research in @jidjournal.bsky.social ready to inform clinical practice. https://bit.ly/4BBski2

    Ver post
  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks blog: Check out insights from the editors of a new, ongoing series of articles in @cidjournal.bsky.social highlighting how experienced clinicians deploy problem-solving skills to navigate complex cases. https://bit.ly/48mkxr0

    Ver post
  • IDSA@idsainfo.bsky.social

    What happens when an antiviral works by causing mutations? In a new Let’s Talk ID episode, JID Deputy Editor Jonathan Li, MD, FIDSA talks the science behind molnupiravir and a recent paper that raised questions about its potential effects in mammalian cells. Watch: www.idsociety.org/multimedia/p...

    Ver post
  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks: Learn more about the efficacy of switching to doravirine/islatravir, how immunocompromised individuals hospitalized with COVID-19 remain at increased mortality risk and other research in @jidjournal.bsky.social to inform clinical practice. https://bit.ly/4AYYFzi

    Ver post
  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks blog: Learn about the poor antimalarial efficacy of IPTp-SP, how starting HIV treatment in early life can significantly reduce the size of the HIV reservoir and other new research in JID that’s ready to inform clinical practice. https://bit.ly/3SI2GGA

    Ver post

Entre para ver mais

Contas que bloqueia

No Bluesky, bloqueios são registros públicos.

Esta conta não bloqueia ninguém.